NTRK1 positive
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene NTRK1
Variant positive
Impact List unknown
Protein Effect unknown
Gene Variant Descriptions NTRK1 positive indicates the presence of NTRK1 mRNA and/or protein.
Associated Drug Resistance
Category Variants Paths

NTRK1 positive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NTRK1 positive gastrointestinal system cancer sensitive GNF-5837 Preclinical - Cell line xenograft Actionable In a preclinical study, GNF-5837 prevented proliferation of transformed rat intestinal epithelial cells expressing Ntrk1 in culture and in xenograft mouse models (PMID: 24900443). 24900443
NTRK1 positive colon adenocarcinoma predicted - sensitive PLX7486 + unspecified CTLA4 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, combination of PLX7486 and anti-CTLA4 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive colon adenocarcinoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). detail...
NTRK1 positive melanoma predicted - sensitive PLX7486 + unspecified CTLA4 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, combination of PLX7486 and anti-CTLA4 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive melanoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). detail...
NTRK1 positive melanoma predicted - sensitive PLX7486 + unspecified PD-1 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, combination of PLX7486 and anti-PD-1 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive melanoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). detail...
NTRK1 positive colon adenocarcinoma predicted - sensitive PLX7486 + unspecified PD-1 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, combination of PLX7486 and anti-PD-1 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive colon adenocarcinoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). detail...